Abstract：Catheter-based renal denervation (RDN) has become a novel technique for the treatment
of resistant hypertension. SymplicityTM System is the first application applied to clinical trials for the
treatment of hypertension. The system has passed the EU's CE certification. The safety and efficacy of
the system have been proved in many clinical trials. More clinical trials and long-term follow-up are ongoing. This review will focus on the characteristics and relevant clinical trials of the radiofrequency ablation catheter system.
李浪，黄江南. SymplicityTM 器械特征及临床研究进展[J]. 中国医疗设备, 2014, 29(5): 5-7.
LI Lang, HUANG Jiang-nan. Characteristics and Research Progress of SymplicityTM System. China Medical Devices, 2014, 29(5): 5-7.
David E Kandzari,Deepak L Bhatt,Paul A Sobotka,et al.Catheter-Based Renal Denervation for Resistant Hypertension:Rationale and Design of the SYMPLICITY HTN-3 Trial[J].Clinical Cardiology,2012,35(9):528-535.
[3]
Expert consensus document from the European Society of Cardiology on catheter-based renal denervation[J]. European Heart Journal doi:10.1093/eurheartj/eht154
[4]
Krum H,Schlaich M,Whitbourn R,et al. Catheter-based renal sympathetic denervation for resistant hypertension: a multicentre safety and proof-of-principle cohort study[J].Lancet, 2009,373(9671):1275-81.
[1]
Howard R Levin,Mark Gelfand.Renal nerve stimulation method and apparatus for treatment of patients,US7162303 B2[P].2007-01-09.
